Significantly altered expression of miR-5-11-3p and its target AKT3 has negative prognostic value in human prostate cancer

被引:23
作者
Zhang, Fan [1 ]
Wu, Zhongjun [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, 1 Youyi Rd, Chongqing 400016, Peoples R China
关键词
Prostate cancer; miR-511-3p; AKT3; Overall survival; Transplantation; MICRORNAS; MIRNAS; PROLIFERATION; BIOGENESIS; MIR-511-3P; BIOMARKERS; RESISTANCE; DIAGNOSIS; GROWTH; CELLS;
D O I
10.1016/j.biochi.2017.06.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose: In this study, we assessed the expression and functions of microRNA-511-3p (miR-511-3p) in human prostate cancer (CaP). Methods: Gene expressions of miR-511-3p in CaP cells and human CaP tumors were assessed by OCR. In VCaP and PD cells, miR-511-3p was overexpressed by lentivirus. The functions of miR-511-3p upregulation in regulating in vitro cancer proliferation, migration and in vivo cancer growth were assessed by MIT, transwell and transplantation assays, respectively. Downstream target gene of miR-511-3p, AKT3, was verified by dual-luciferase activity and qPCR assays. AKT3 was then overexpressed in miR-511-3p-upregulated CaP cells to assess its functions in miR-511-3p-mediated cancer regulation. Results: MiR-511-3p is significantly downregulated in CaP cell lines, and human CaP tumors. MiR-511-3p was further downregulated in T3/T4-staged CaP tumors and closely correlated with shorter overall survival among CaP patients. In VCaP and PC3 cells, lentiviral-induced miR-511-3p upregulation was acting as a tumor suppressor by inhibiting in vitro cancer proliferation, migration and in vivo transplantation. Human AKT3 gene was confirmed to be the downstream target of miR-511-3p in CaP. In miR511-3p-upregulated VCaP and PD cells, forced-overexpression of AKT3 reversed the tumor suppressive effects of miR-511-3p in CaP. Conclusion: MiR-511-3p may serve as a prognostic factor and tumor suppressor in CaP, very likely through inverse regulation of its downstream target gene of AKT3. (C) 2017 Published by Elsevier B.V.
引用
收藏
页码:66 / 72
页数:7
相关论文
共 34 条
[21]   Immunotherapy for prostate cancer: recent developments and future challenges [J].
Schweizer, Michael T. ;
Drake, Charles G. .
CANCER AND METASTASIS REVIEWS, 2014, 33 (2-3) :641-655
[22]  
Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI [10.3322/caac.21387, 10.3322/caac.21669, 10.3322/caac.21654]
[23]   Endogenous RNAs Modulate MicroRNA Sorting to Exosomes and Transfer to Acceptor Cells [J].
Squadrito, Mario Leonardo ;
Baer, Caroline ;
Burdet, Frederic ;
Maderna, Claudio ;
Gilfillan, Gregor D. ;
Lyle, Robert ;
Ibberson, Mark ;
De Palma, Michele .
CELL REPORTS, 2014, 8 (05) :1432-1446
[24]   miR-511-3p Modulates Genetic Programs of Tumor-Associated Macrophages [J].
Squadrito, Mario Leonardo ;
Pucci, Ferdinando ;
Magri, Laura ;
Moi, Davide ;
Gilfillan, Gregor D. ;
Ranghetti, Anna ;
Casazza, Andrea ;
Mazzone, Massimiliano ;
Lyle, Robert ;
Naldini, Luigi ;
De Palma, Michele .
CELL REPORTS, 2012, 1 (02) :141-154
[25]   Deregulated Akt3 activity promotes development of malignant melanoma [J].
Stahl, JM ;
Sharma, A ;
Cheung, M ;
Zimmerman, M ;
Cheng, JQ ;
Bosenberg, MW ;
Kester, M ;
Sandirasegarane, L ;
Robertson, GP .
CANCER RESEARCH, 2004, 64 (19) :7002-7010
[26]   miRNAs: Their discovery, biogenesis and mechanism of action [J].
Tetreault, N. ;
De Guire, V. .
CLINICAL BIOCHEMISTRY, 2013, 46 (10-11) :842-845
[27]   Current Approaches, Challenges and Future Directions for Monitoring Treatment Response in Prostate Cancer [J].
Wallace, T. J. ;
Torre, T. ;
Grob, M. ;
Yu, J. ;
Avital, I. ;
Bruecher, Bldm ;
Stojadinovic, A. ;
Man, Y. G. .
JOURNAL OF CANCER, 2014, 5 (01) :3-24
[28]   Role of MicroRNAs in Prostate Cancer Pathogenesis [J].
Wang, You-Lin ;
Wu, Shuai ;
Jiang, Bo ;
Yin, Fu-Fen ;
Zheng, Shuai-Shuai ;
Hou, Si-Chuan .
CLINICAL GENITOURINARY CANCER, 2015, 13 (04) :261-270
[29]  
Wen X, 2014, AM J CLIN EXP UROL, V2, P219
[30]   MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3 [J].
Wu, Huijuan ;
Xiao, Zhenghua ;
Zhang, Hua ;
Wang, Ke ;
Liu, Wenxin ;
Hao, Quan .
ANTI-CANCER DRUGS, 2014, 25 (07) :799-809